Understanding
immunogenicity is a key challenge in the development of therapeutics with many biologics inducing undesirable immune responses directed towards the therapeutic resulting in reduced efficacy, anaphylaxis and occasionally life threatening autoimmunity. This conference explores the latest updates on the prediction and reduction of
immunogenicity, clinical results and interpetations and optimising bioassays.
Led by selected case studies from leading drug developement teams, bioanalytical experts, and academics we aim to provide the insights and sharing necessary to deliver safe, efficacious large molecule drugs to improve the lives of patients.
Benefits of Attending
- Gain an understanding of immunogenicity and challenges in biologics development
- Explore tolerance induction techniques in detail
- Discover the latest in pre-clinical model
- Learn more about neutralising antibody assay best practice
- Receive updates on the ABIRISK project
Plus An Interactive Half-Day Post-Conference Workshop | Wednesday 1st July 2015
Tools for early immunogenicity risk assessment and reductionWorkshop leaders: Sofie Pattijn, CTO, ImmunXperts SA and
Morten Nielsen, Associate Professor, Center for Biological Sequence Analysis, Technical University of Denmark
8.30am - 12.30pm
Speakers
- Annie De Groot, CEO and CSO, EpiVax, Inc.
- Bassam Hallis, Head of Pre-Clinical Development, Public Health England
- Bernard Maillere, Research Director and Head, Immunology Laboratory, Institute of Biology and Technologies
- Chloe Ackaert, Postdoctoral Researcher, Cellular and Molecular Immunology, Free University Of Brussels
- David Wraith, Chief Scientific Officer and Founder, Apitope International NV
- Emma Smith, Senior Group Leader, UCB
- Farnaz Fallah-Arani, Group Leader, Pharmacology, UCB
- Gerhard Niederfellner, Head of Tumour Cell Biology, Pharma Research & Early Development, Roche Innovation Center Penzberg
- Gisella Puga Yung, Scientific Collaborator II, University Of Geneva
- Grzegorz Kijanka, Postdoctoral Researcher, Leiden Academic Centre for Drug Research, Leiden University
- Guilhem Richard, Computational Immunologist, EpiVax Inc
- Jeremy Fry, Assay Specialist, ProImmune Ltd.
- Kei Kishimoto, Chief Scientific Officer, Selecta Biosciences
- Linglong Zou, Director of Experimental Immunology, Teva Pharmaceuticals
- Margareta Wiken, Bioanalytical Manager, Swedish Orphan Biovitrum
- Marsilio Adriani, Postdoctoral Research Associate, University College London
- Morten Nielsen, Associate Professor, The Technical University Of Denmark
- Sandra Garces, Rheumatologist Consultant and Researcher, Garcia de Orta’s Hospital
- Shivanthy Visvalingam, Manager EU Regulatory Strategy for Biosimilars, Pfizer
- Sofie Pattijn, Chief Technology Officer, ImmunXperts
Please fill in your name and email to receive the conference agenda of this event.
The agenda is available as PDF under downloads at the right side of the page.
Venue
The venue is not yet available for this event.
Follow this event to be informed when the venue is available and stay informed on other changes.
Venue
Marriott Hotel, Regents Park128 King Henry's Road
London, NW3 3ST
United Kingdom
